Market Outlook: Solid Ground or Thin Ice?

In July, the U.S. economy suffered from a 32.9% contraction in GDP, the largest in recent history. Despite this volatility, biotech venture funding and IPOs have reached record highs in 2020. Will investors remain confident in biotechnology companies? Are there best practices that company executives and business development professionals should consider for fundraising and deal making? Attend to hear success stories and challenges as economic, political, and public health uncertainty remains on the forefront.